- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05567185
En studie av Erdafitinib Intravesical Delivery System hos japanske deltakere med blærekreft (TAR-210)
En fase 1-studie for å evaluere tolerabiliteten, sikkerheten og farmakokinetikken til TAR-210 hos japanske deltakere med blærekreft og utvalgte FGFR-mutasjoner eller fusjoner
The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Kanagawa, Japan, 216 8511
- St Marianna University Hospital
-
Osaka, Japan, 541 8567
- Osaka International Cancer Institute
-
Toyama, Japan, 930-0194
- Toyama University Hospital
-
Tsukuba, Japan, 305 8576
- University of Tsukuba Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed non-muscle-invasive urothelial carcinoma of the bladder
- All visible tumors must be completely resected prior to the start of study treatment and documented on screening cystoscopy
- Confirmed recurrence of non-muscle invasive bladder cancer (NMIBC) after prior therapy that meet either one: a. Recurrence of high-risk NMIBC (high-grade Ta or any-grade T1) within 12 months after adequate Bacillus Calmette-Guerin (BCG), or any-grade T1 within 3 months after 1st induction course, refusing or ineligible for radical cystectomy (RC). b. Recurrence of intermediate- or high-risk NMIBC (any-grade Ta/T1) after prior BCG regardless of the timing of recurrence, refusing or ineligible for RC and considering no other effective treatment options. c. Recurrence of intermediate-risk NMIBC (low grade Ta) after intravesical chemotherapy including maintenance therapy following a single dose after operation, no other effective intravesical chemotherapy is available and refusing BCG treatment
- At least 1 of the study protocol defined activating fibroblast growth factor receptors (FGFR) mutation or fusion, as determined by local or central testing using either tumor tissue or urine sample collected prior to trans urethral resection of bladder tumour (TURBT)
- Eastern Cooperative Oncology Group (ECOG) performance status score of less than or equal to (<=) 2
Exclusion Criteria:
- Histologically confirmed muscle-invasive (T2 or higher stage) urothelial carcinoma of the bladder.
- Prior treatment with an fibroblast growth factor receptor (FGFR) inhibitor
- Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe placement, indwelling use, or removal of erdafitinib intravesical delivery system
- Participants with active bladder stones or history of bladder stones less than [< 6] months prior to the start of study treatment
- Participants have concurrent or second malignancy other than the disease which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s); -Bladder post-void residual volume (PVR) >350 mL after second voided urine, -Current central serous retinopathy or retinal pigment epithelial detachment of any-grade
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose Escalation: Erdafinitib Intravesical Delivery System
Participants with bladder cancer and fibroblast growth factor receptor (FGFR) mutations or fusions will receive erdafitinib intravesical delivery system and study will evaluate 2 dose levels of erdafitinib. Participants with a complete response (CR) may continue to receive treatment up to a duration of 1 year as long as there is no disease recurrence or progression, intolerable toxicity or withdrawal of consent. |
Erdafitinib intravesical delivery system will be administered.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Dose-limiting Toxicity (DLT)
Tidsramme: Up to 28 days
|
Number of participants with DLT will be assessed. The DLTs are specific adverse events related to erdafitinib intravesical delivery system and are defined as any of the following: high grade non-hematologic toxicity or hematologic toxicity. |
Up to 28 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma Concentration of Erdafitinib
Tidsramme: Up to 180 days
|
Plasma concentration of erdafitinib will be reported. |
Up to 180 days
|
|
Urine Concentration of Erdafitinib
Tidsramme: Up to 180 days
|
Urine concentration of erdafitinib will be reported. |
Up to 180 days
|
|
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to 3 years 10 months
|
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. |
Up to 3 years 10 months
|
|
Number of Participants with AEs by Severity
Tidsramme: Up to 3 years 10 months
|
Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 3 years 10 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Janssen Pharmaceutical K.K., Japan Clinical Trial, Janssen Pharmaceutical K.K.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Beinsykdommer
- Muskel- og skjelettsykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Urologiske neoplasmer
- Kraniofaciale abnormiteter
- Muskuloskeletale abnormiteter
- Medfødte abnormiteter
- Urinblæresykdommer
- Bensykdommer, utviklingsmessige
- Lemdeformiteter, medfødt
- Synostose
- Dysostoser
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Kraniosynostoser
- Syndaktyli
- Neoplasmer i urinblæren
- Acrocephalosyndactylia
- erdafitinib
Andre studie-ID-numre
- CR109248
- 42756493BLC1004 (Annen identifikator: Janssen Research & Development, LLC)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .